Tumor-associated macrophages (TAMs) are highly expressed within the tumor microenvironment of a wide range of cancers where they exert a pro-tumor phenotype by promoting tumor cell growth and suppressing anti-tumor immune function. Here, we showed that TAM accumulation in human and mouse tumors correlates with tumor cell expression of integrin αvβ3, a known driver of epithelial cancer progression and drug resistance. A monoclonal antibody targeting αvβ3 (LM609) exploited the co-enrichment of αvβ3 and TAMs to not only eradicate highly aggressive drug-resistant human lung and pancreas cancers in mice, but prevent the emergence of circulating tumor cells. Importantly, this anti-tumor activity in mice was eliminated following macrophage depletion. While LM609 had no direct effect on tumor cell viability, it engaged macrophages but not natural killer (NK) cells to induce antibody-dependent cellular cytotoxicity (ADCC) of αvβ3-expressing tumor cells despite their expression of the CD47 "don't eat me signal".
Introduction
Integrin αvβ3 is a marker of angiogenic blood vessels in cancer [1, 2] , and its expression on tumor cells has been linked to cancer progression, drug resistance, and epithelial-tomesenchymal transition (EMT) [3, 4] . As such, two primary drugs targeting αvβ3 have advanced to clinical testing, including a monoclonal antibody (etaracizumab) and a cyclic peptide antagonist (cilengitide). These agents, while safe, produced only modest clinical activity in the patient populations tested.
Cilengitide, a selective cyclic peptide inhibitor of integrins αvβ3 and αvβ5, produced encouraging results in phase 1/2 trials for patients with advanced glioblastoma multiforme [5, 6] , yet ultimately failed to meet overall survival endpoints in phase 3 [7] . A subsequent correlative immunohistochemical study revealed that higher αvβ3 protein levels were associated with improved survival for patients treated with cilengitide [8] , suggesting that certain subsets of patients may be particularly sensitive to this drug. In fact, we recently identified a subset of tumors within the "proneural" and "classical" subtypes of glioblastoma that are addicted to aberrant signaling from integrin αvβ3, making them highly sensitive to agents, including cilengitide, that disrupt the pathway [9] . Thus, it is tempting to speculate that cilengitide would have been able to meet the survival endpoints for a more defined subset of glioblastoma patients.
The monoclonal anti-αvβ3 antibody etaracizumab has been tested in patients with several types of solid tumors, including a small cohort of patients with metastatic renal cancer where it was able to prolong stable disease for 3 patients [10] . Despite a good safety profile, etaracizumab did not slow disease progression in patients with sarcoma, prostate, or colorectal cancers [10] .
Interestingly, this antibody was tested in a phase 2 trial (NCT00072930) for patients with metastatic prostate cancer in combination with standard of care docetaxel, prednisone, and zoledronic acid. Notably, steroids such as prednisone have been associated with inferior immunotherapy responses [11] , while zoledronic acid can block the activity of M2 macrophages [12] . Similarly, etaracizumab was tested in a phase 2 trial for melanoma in combination with the standard of care, dacarbazine [13] . In this trial, the overall survival for patients treated with etaracizumab was 12.6 months, while patients treated with etaracizumab plus dacarbazine had a worse overall survival (9.4 months), compared with historical data for dacarbazine alone (6-10 months) [13] . In addition to acting as a cytotoxic agent for tumor cells, dacarbazine also produces immunosuppressive effects within the tumor microenvironment, including inhibition of M2 macrophage activity [14] . Together, these clinical trial results suggest that the monoclonal antibody etaracizumab may improve survival in the context of immune effector cells.
Monoclonal antibodies have emerged as a class of anti-cancer therapeutics to not only directly kill tumor cells, but to manipulate anticancer immune responses [15] . The activity of several FDA approved anti-cancer antibodies such as anti-CD20 (Rituximab) and anti-EGFR (Cetuximab) have been attributed to their ability to induce antibody-dependent cellular cytotoxicity (ADCC) [16, 17] . This process is triggered when antibodies bind to tumor cell antigens and are simultaneously recognized by Fcγ receptors on immune effector cells, including natural killer (NK) cells, monocytes, macrophages, neutrophils, and dendritic cells [18] .
While not present in early stage disease, integrin αvβ3 becomes enriched during epithelial cancer progression, in particular as tumors lose sensitivity to standard of care [19] . As such, integrin αvβ3 represents an ideal tumor antigen to mount an attack against. Here, we show that αvβ3 on epithelial cancers positively correlates with the accumulation of tumor-associated macrophages (TAMs) within the tumor microenvironment, immune cells that typically lead to tumor progression and immune suppression. Interestingly, TAMs armed with an anti-αvβ3 antibody can be activated to kill the highly aggressive αvβ3+ CD47+ epithelial cancer cells via ADCC and thereby suppress cancer progression and drug resistance. Our work reveals a potentially valuable subpopulation of patients who might be particularly sensitive to the effects of 5 an αvβ3-targeted antibody, namely those with advanced epithelial cancers whose tumors have become co-enriched for integrin αvβ3 and TAMs. experiments. Anti-αvβ3 antibody, LM609, was produced as previously described [21] . Batch to batch activity is confirmed by adhesion assays. Antibodies are listed in Supplemental Table 1 .
Materials and Methods

Statistics
Gene expression analysis using public databases mRNA expression in TCGA datasets was used to analyze the correlation between ITGB3 and immune cell type scores, calculated as previously described [22] using cBioPortal. Gene sets for immune cell markers are listed in Supplemental Table 2 .
Correlation analysis of ITGB3 and immune cell types using NanoString nCounter 10 pre-existing, de-identified lung adenocarcinoma frozen tissue biopsies were obtained from the Moores UCSD Cancer Center Biorepository. mRNA was extracted using the RNeasy Mini Kit (Qiagen, 74104). The quality of extracted mRNA was tested using Agilent Bioanalyzer (Agilent).
Expression of mRNAs involved in immune cell activities was analyzed using nCounter®
PanCancer Immune Profiling Panel (NanoString).
Protein analysis
Immunohistochemical staining
Immunohistochemical staining was performed on FFPE slides using the VECTASTAIN Elite ABC 
Immunofluorescence staining
Immunofluorescence staining was performed on frozen sections permeabilized with 0.1%
TritonX-100 (Bio-Rad, 1610407) in PBS for one minute, blocked with 10% NGS (Jackson ImmunoResearch, 005-000-121) in PBS for two hours, and incubated with DAPI (Life Technologies, 62248, 1 µg/mL in 1% BSA in PBS) and an anti-mouse F4/80 antibody (eBioscience 14-4801-82, conjugated with Texas Red fluorophore by OneWorldLab) for two hours at room temperature. Images were acquired utilizing a Nikon Eclipse C2 confocal microscope (Nikon). F4/80-positive area fraction with respect to tumor tissue was calculated utilizing ImageJ (NIH) [23] .
Flow cytometry
Cell pellets were washed with PBS, blocked with 1% BSA in PBS for 30 minutes at room temperature and stained with indicated primary antibodies or IgG isotype controls with or without fluorescently labeled secondary antibodies. Cells were incubated with propidium iodide (Sigma, P4864), then flow cytometry was performed on a BD LSRFortessa™ and analyzed using FlowJo (Treestar) software.
In vitro functional assays 8
MTT (cell viability) assay
Cells in 96-well plates were incubated in thiazolyl blue tetrazolium bromide solution (Sigma, M2128) for two hours at 37°C. After the solution was removed, the blue crystalline precipitate in each well was dissolved in DMSO. Visible absorbance at 560 nm was quantified using a microplate reader.
Antibody-dependent cellular-cytotoxicity (ADCC) assay
Target cells stained with CFSE Cell Division Tracker Kit (BioLegend, 423801) were co-cultured with effector cells with or without isotype IgG or LM609 for 5-16 hr at 37°C, stained with PI, and flow cytometry was performed on BD LSRFortessa™. The ratio of dead target cells (PI-positive)
to the total target cell population (CFSE-positive) was calculated as described [24] .
Antibody-dependent cellular phagocytosis (ADCP) assay
Target cells stained with CFSE Cell Division Tracker Kit (BioLegend, 423801) were co-cultured with effector cells stained with CellTrace™ Far Red Cell Proliferation Kit (Thermo, C35464), with or without isotype IgG or LM609 for 5 hr at 37°C. The ratio of CFSE-Far Red double positive cells was calculated using flow cytometry as described [24] .
Mouse tumor experiments
Study approval
All experiments involving mice were conducted under protocol S05018 approved by the UC San Diego Institutional Animal Care and Use Committee. All studies are in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Isolation of tumor-associated macrophages (TAMs) from mice
TAMs were isolated from tumor tissues as described [25] . 
Isolation of bone marrow derived macrophages (BMDMs) from mice
BMDMs were aseptically harvested from euthanized 8-10 week-old female C57BL/6 mice by flushing leg bones with RPMI, filtering through 70 µm cell strainers, and incubating in Red Blood
Cell Lysing Buffer Hybri-Max™ (Sigma, R7757). Cells were incubated with mouse M-CSF (Peprotech, 315-02) for 7 days before ADCC assays.
Isolation of NK cells from mice
Splenocytes were aseptically harvested from euthanized 8-10 week-old female C57BL/6 mice by mincing spleens with PBS containing 2 % FBS and 1 mM EDTA, filtering through 40 µm strainers, and incubating in Red Blood Cell Lysing Buffer Hybri-Max™ (Sigma, R7757). NK cells were isolated from splenocytes using NK Cell Isolation Kit II (Miltenyi, 130-096-892).
Isolation of human peripheral blood mononuclear cells (PBMCs) and macrophages
Leukoreduction system chambers (LRSC) were purchased from the San Diego Blood Bank.
PBMCs were isolated from LRSC using Histopaque-1083 (Sigma, 10831) following the manufacturer's protocol. To obtain macrophages, PBMCs were incubated in tissue culture plates with human M-CSF (Peprotech, 300-25) for 5 days.
Genotyping of FcγR polymorphism
Genomic DNA was isolated from donor blood using Genomic DNA Mini Kit (Invitrogen, K1820-00). DNA was analyzed for FcγRlla (rs1801274) and llla (rs396991) polymorphisms using TaqMan SNP Genotyping Assays (Life Technologies, 4351379).
Isolation of erlotinib-resistant tumor cells from mouse tumors
Erlotinib resistant HCC827 (HCC827-R) cells and PC9 (PC9-R) cells were established as previously described [19] . 
Lung xenograft model with acquired resistance to erlotinib
An erlotinib resistant lung adenocarcinoma xenograft model was utilized as previously described [26] . Briefly, HCC827 (5 × 10 6 tumor cells in 100 μl of PBS) cells were subcutaneously injected to the right flank of female nu/nu mice (Charles River, 088, 8-10 weeks old). Tumors were measured with calipers twice per week. Animals with a tumor volume of 250-700 mm 3 were randomly assigned into groups treated with combinations of Captisol (oral, six times/week), PBS (i.p., twice/week), LM609 (i.p., 10 mg/kg, twice/week), or erlotinib (oral, 6.25 mg/kg, six times/week).
Vehicle-treated mice were sacrificed on day 15 due to large tumor size, and erlotinib groups on day 50. Tumors were placed into liquid nitrogen, OCT compound, or 10% formalin. Alternatively, Erlotinib sensitive HCC827 (HCC827-P) and PC9 (PC9-P) and resistant HCC827 (HCC827-R18) and PC9 (PC9-R4L) cells were isolated. Tumor growth and αvβ3 expression are shown in Supplemental Figure 3 .
Orthotopic lung adenocarcinoma xenografts and CTC isolation
Luciferase-and GFP-positive HCC827 cells (5 × 10 6 cells in 50 μl of PBS) were injected into the lungs of female nu/nu mice (8-10 weeks old) and tumor growth monitored by bioluminescence imaging (IVIS Spectrum). Eight weeks after injection, mice were randomly divided into groups:
vehicle (6% Captisol, oral, six times/week), erlotinib (oral, 6.25 mg/kg, six times/week), or the combination of erlotinib and LM609 (i.p., 10 mg/kg, twice/week). Whole blood (0.5 mL/mouse) was collected in EDTA tubes, and PBMCs including CTCs were isolated using Lymphoprep™ (STEMCELL Technologies, 07801) and SepMate™ (STEMCELL Technologies, 15415). Cells were washed with PBS, plated on poly-L-Lysine coated 8-well chamber plates, fixed with 4% PFA, and stained with DAPI (1 µg/mL in 1% BSA in PBS), LM609 (5 µg/mL in 1% BSA in PBS), and a fluorescently-labeled secondary antibody. The number of αvβ3+ and αvβ3-CTC (DAPI+/GFP+) were counted using a Nikon Eclipse C2 confocal microscope (Nikon).
Results
Integrin αvβ3 positively correlates with macrophage markers across multiple cancers
During cancer progression, the tumor microenvironment becomes dramatically altered with the appearance of various stromal and immune cells that influence the malignant behavior of the tumor [27, 28] . Accordingly, it is important to consider what immune cells are available when targeting tumors with therapeutic antibodies. Although the enrichment of integrin αvβ3 in tumor cells is a driver of an aggressive, drug resistant tumor phenotype [20, 26] , the impact of αvβ3-positive tumor cells on the tumor immune microenvironment has not been well defined. We therefore queried multiple TCGA datasets to identify whether β3-expressing tumors may be enriched for certain immune effector cell types that could contribute to antibody-mediated killing.
This analysis reveals that mRNA expression of ITGB3 positively correlates (rho≥0.3) with marker sets for macrophages (MΦ), dendritic cells (DC), and neutrophils (NΦ), but not with NK cells (NK)
for certain types of solid tumors (Figure 1A) . For example, ITGB3 mRNA expression positively correlates with macrophage markers for kidney, breast, GBM, lung, stomach, prostate, pancreas, esophageal, and colorectal cancers, while no correlation is observed for renal papillary, sarcoma, thyroid, melanoma, and ovarian cancers ( Figure 1A) . Also, ITGB3 positively correlates with other immune cell types such as mast cells, T cells and B cells, but this relationship is observed for a limited number of tumor types ( Figure S1A) . Interestingly, no correlation between ITGB3 and immune cell markers is observed for thyroid, melanoma, kidney papillary, and sarcoma despite these cancers having the highest median expression of ITGB3 across the TCGA pan-cancer dataset ( Figure S1B) .
The positive correlation of β3 and immune cell type markers was validated for an independent tumor sample set of 10 frozen lung adenocarcinoma biopsies analyzed using the NanoString nCounter platform (Figure 1B) . Even for this modest sample size, tumors with above median ITGB3 expression are enriched for markers characterizing macrophages, dendritic cells, and neutrophils (but not NK cells) compared with tumors having below median ITGB3 expression.
Consistent with the analysis of TCGA datasets, there is a strong positive correlation between ITGB3 and these marker sets. Together, these data suggest that β3-positive epithelial cancers may be enriched for multiple cell types that could serve as effector cells for antibody-mediated therapy.
To further validate the positive correlation of the enrichment of macrophages with β3 expression on tumor cells at the protein level for a variety of genetically and histologically distinct 13 solid tumor types, we performed immunohistochemical staining for a series of commercially available tumor microarray slides. This analysis reveals that integrin β3 protein expression on tumor cells positively correlates with the presence of macrophage markers CD68 and CD163 for lung, prostate, colorectal, kidney, and glioblastoma tumors ( Figure 1C) . Higher magnification images show that individual areas with integrin β3 staining on tumor cells are enriched for cells that stain positive for the macrophage markers ( Figure S2) . Notably, the percent of tumors with positive tumor cell expression of β3 ranges from 29-54% among the array slides examined, indicating there is a significant portion of β3+ tumors across this diverse population of tumor types, grades, and stages. Together, these findings indicate that tumors with high tumor cell expression of integrin β3 are particularly enriched for TAMs, a component of the tumor microenvironment that contributes to tumor progression [29] , and that these cells might prove important when targeting tumors with certain therapeutic antibodies.
An anti-αvβ3 monoclonal antibody triggers macrophage-mediated tumor cell killing
Considering the co-enrichment of TAMs and integrin αvβ3-expressing tumor cells, we reasoned that exploiting this relationship could provide a basis for a therapeutic strategy to treat αvβ3+ cancers. To do this, we used a function blocking monoclonal antibody we previously developed, LM609, which recognizes integrin αvβ3 on human but not mouse cells [30] and served as the parent antibody for a fully humanized version, Vitaxin/etaracizumab [31, 32] . Indeed, we find that αvβ3-expressing human lung and pancreatic xenograft tumors growing in nude mice are highly sensitive to LM609, and that this effect can be completely blocked by macrophage depletion using clodronate liposomes (Figure 2A) , demonstrating that TAMs play a critical role in the anti-tumor efficacy of this tumor-targeted antibody.
An enrichment of TAMs has been observed following cancer therapy, including the EGFR inhibitor erlotinib [33] , and we previously reported that integrin αvβ3 is upregulated during the acquisition of erlotinib resistance in lung cancers in mice and for the BATTLE trial in man [19] .
Accordingly, we show that αvβ3-negative HCC827 human EGFR mutant lung tumors not only gain αvβ3 as they become drug resistant, but they also become enriched for TAMs ( Figure 2B) .
As expected, LM609 alone has no effect on the growth of HCC827 xenograft tumors prior to the development of drug resistance due to lack of the αvβ3 antigen (Figure 2C) . While mice treated with erlotinib alone show an initial reduction in tumor size, this is followed by an eventual tumor re-growth and gain in αvβ3 expression ( Figure 2C) . In contrast, the combination of erlotinib plus LM609 prolongs drug sensitivity and prevents the appearance of integrin β3 (Figure 2C) .
Interestingly, this combined treatment does not reverse the macrophage enrichment that emerges during erlotinib treatment (Figure S3B ).
Since the appearance of circulating tumor cells (CTC) represents a hallmark of tumor progression and EMT [34, 35] , we considered whether LM609 might suppress this indicator of aggressive disease. Whereas orthotopic HCC827 lung tumors gain αvβ3 expression during erlotinib therapy and show a marked increase of CTCs in the blood after 4 weeks of therapy, combining LM609 with an EGFR inhibitor prevents the appearance of CTCs in this setting ( Figure   2D ). Together, our results indicate that the monoclonal antibody LM609 requires macrophages for its anti-tumor activity in mouse xenograft models, and we demonstrate its efficacy for both highly aggressive tumors with constitutive αvβ3 expression as well as those that gain αvβ3 during acquired resistance to therapy. Moreover, by eliminating those tumor cells that become enriched for αvβ3 during EGFR inhibitor treatment, we can suppress cancer progression as measured by a decrease in the appearance of CTC.
LM609 induces macrophage-mediated antibody-dependent cellular cytotoxicity (ADCC) rather than phagocytosis
To confirm that the mechanism of action for LM609 is macrophage dependent, we asked whether LM609 can kill tumor cells in vitro using TAMs, an abundant source of immune effector cells that are co-enriched with β3 (Figure 1) and which typically play a pro-tumor role [36] . Indeed, LM609 shows robust activity using TAMs isolated from mouse Lewis lung carcinoma (LLC) tumors grown in immune-competent C57BL6 mice or immune-compromised athymic nude mice ( Figure   3A) . The antibody can also kill tumor cells using human monocyte-derived macrophages isolated from healthy donor blood, as well as bone marrow derived macrophages (BMDM) isolated from healthy mice (Figure 3B, S4A) . Binding of the antibody to Fc receptors on macrophages is critical for its killing capacity, since there is no macrophage-mediated killing in the presence of an antibody blocking of the Fc receptors CD16, CD32, and CD64, and a form of LM609 lacking the Fc portion (Fab LM609) cannot trigger macrophage-mediated killing (Figure 3C-D) . To our surprise, LM609-mediated ADCC is not achieved with mouse NK cells or peripheral blood mononuclear cells (PBMCs) isolated from human blood (Figure 3E) , immune effector cell types to which antibodies are commonly engineered for optimal binding [37, 38] . In fact, NK cells are not correlated with β3 expression in tumors (Figure 1) . Together, these findings suggest that the anti-tumor activity of LM609 involves the opsonization of αvβ3-expressing tumor cells with the monoclonal antibody, followed by the subsequent engagement of macrophage Fc receptors to induce killing.
Monoclonal antibodies can direct macrophages to induce tumor cell killing through two primary mechanisms, processes known as antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC). Here, we show that LM609 induces macrophage ADCC, but not ADCP or direct killing, and this requires integrin β3 expression ( Figure 3F and S4B-C) . The lack of an ADCP response is consistent with high tumor cell expression of CD47, the "don't eat me" signal [39] that tumor cells often exploit to evade phagocytosis (Figure 3F and S4B) . Although αvβ3 and other integrins are binding partners for CD47 [40] , CD47 expression is not impacted by β3 ectopic expression or knockout (Figure 3F and S4B). Macrophage-mediated ADCC but not ADCP or direct killing is also observed for additional αvβ3-expressing tumor cell lines representing tumor types for which ITGB3 expression is linked to macrophage enrichment (Figure 1) , including lung, pancreas, brain, and kidney cancer ( Figure 3G) . We also show that LM609 can induce macrophage-mediated ADCC for the drug resistant cells, but not drug sensitive cells, suggesting that the prevention of drug resistance seen in Figure 2C is due to macrophage ADCC (Figure 3H) . Taken together, our findings demonstrate that the anti-tumor activity of LM609 results from its ability to engage αvβ3 on tumor cells along with Fcγ receptors on macrophages isolated from peripheral blood monocytes, healthy bone marrow, or tumor tissues to kill αvβ3-positive tumor cells, including those from a subset of cancers for which ITGB3 expression is co-enriched with macrophage markers.
Discussion
Our findings that the antitumor properties of LM609 depend on macrophages and their ability to initiate ADCC suggests a new therapeutic strategy for a range of epithelial cancers.
Humanized versions of LM609 (MEDI-522, Vitaxin, or etaracizumab) have been tested in phase 1 clinical trials and were shown to be relatively non-toxic [10, 13, 32] . However, in phase 2 trials melanoma patients with etaracizumab alone resulted in a 12.6 month overall survival rate which was decreased to 9.4 months when combined with dacarbazine, a highly immune-suppressive drug that inhibits macrophage activation [13] , suggesting that immune cells may contribute to the increased survival observed for patients treated with the antibody alone. Indeed, we show that depletion of macrophages using clodronate liposomes dramatically reduces the therapeutic effect of LM609 in lung or pancreas tumors in mice. Furthermore, our observation that αvβ3 and macrophage markers are not co-enriched in the TCGA melanoma dataset also suggests that melanoma patients may not be the ideal population for a drug like LM609 that exploits this relationship. Instead, we show the potential of combining LM609 with a first-line therapy such as EGFR blockade to prolong drug sensitivity by eliminating drug resistant αvβ3+ tumor cells ( Figure  2C ) and suppress tumor progression as measured by the elimination of CTCs (Figure 2D) .
Together, these results indicate that the enrichment of TAMs in αvβ3-expressing tumors renders them amenable to a therapeutic approach that redirects the pro-tumor immune effector cells to attack the tumor.
Our findings provide a general rationale for focusing future efforts on the development of monoclonal antibodies capable of recruiting macrophages. In the tumor microenvironment, the anti-tumor function of cytotoxic T cells and NK cells are compromised, while the recruitment and expansion of pro-tumor macrophages is enhanced [41] . TAMs secrete growth factors and cytokines to promote tumor progression through induction of angiogenesis, metastasis, and immunosuppression [25, 28, 36, 42, 43] . As observed for EGFR inhibitor resistant lung adenocarcinoma patient tumors [33, 44] , we find that drug-resistant tumors contain more TAMs than tumors from vehicle-treated mice (Figure 2B) . Thus, a strategy to arm macrophages to attack tumor cells may be particularly useful for drug-resistant cancers. Although therapeutic antibodies are commonly screened in vitro for their ability to engage Fc receptors on NK cells, we reasoned that an antibody capable of engaging macrophages may provide a more powerful therapeutic strategy for αvβ3-expressing tumors that feature an abundance of TAMs.
Furthermore, considering that PD-L1 (CD274) expression is positively correlated with ITGB3 in many of those cancers that had ITGB3-macrophage marker positive correlation (Figure S1A) , this therapeutic strategy may ultimately provide efficacy in combination with a PD-L1 inhibitor.
The mechanism of action we show for LM609 is fundamentally different than a number of recent strategies to "target" macrophages by blocking their tumor-promoting activities or exploiting potential anti-tumor effector functions [45] . Our data suggests that exploiting TAMs as effector cells for antibody killing does not require a certain macrophage phenotype, since ADCC was triggered using macrophages isolated from healthy human blood donors, mouse bone marrow, or tumors from either C57BL6 or athymic nude mice. While LM609 does not appear to induce phagocytosis (Figure 3F and G) , several antibody therapeutics do utilize this mechanism, including anti-CD20 (rituximab) and anti-EGFR (cetuximab). Because the lung cancer cells we tested express high levels of CD47 (Figure 3F and S4B) , this "don't eat me" cell surface marker [39] may account for the lack of a phagocytosis response. Indeed, the combination of cetuximab with an anti-CD47 antibody dramatically increases macrophage ADCP in preclinical models [46] and is currently being tested in clinical trials for colorectal cancer. Combining such an approach with LM609 may further enhance its activity in vivo, especially for tumors that may be particularly enriched for CD47 [47] .
Interestingly, LM609 was not able to induce NK-mediated ADCC for any of the endogenous αvβ3-expressing human lung, pancreas, brain or kidney cancer cells examined.
Mechanistically, we show that LM609-mediated killing utilizing macrophages requires Fcγ receptors typically found on macrophages (Figure 3C) , and that macrophage depletion negates the anti-tumor effect of the antibody in vivo (Figure 2A ). However, it is possible that LM609 could utilize other known ADCC effector cells including neutrophils and dendritic cells, especially since markers for these cell types show positive correlations with ITGB3 expression in patient tissues ( Figure 1A) . It is more difficult to determine if the reduction of αvβ3-expressing circulating tumor cells (CTCs) in mice treated with the combination of erlotinib and LM609 (Figure 2D) is a result of macrophage-mediated ADCC within the circulation, or whether LM609 is able to reduce the aggressive nature of the primary tumor. Also, it is interesting to consider whether LM609 therapy alters the phenotype of TAMs by virtue of eliminating αvβ3-expressing tumor cells. Our work provides the rationale for a closer examination of how tumor progression and response to therapy depends on the unique relationship between TAMs and αvβ3-expressing tumor cells.
In conclusion, our study demonstrates that αvβ3-expressing tumors are enriched for macrophages and highlights how this scenario can be manipulated using antibody therapeutics to exploit these two elements (Figure 4) . Indeed, an anti-αvβ3 antibody encourages macrophages to selectively destroy the αvβ3+ drug-resistant tumor cells within the primary tumor as well as CTCs, together delaying the onset of therapy resistance and potentially slowing disease progression. Because LM609 only recognizes human integrin αvβ3, utilizing human xenograft tumors in mice allows us to separate its ability to induce ADCC from any impact on host-derived macrophages or tumor-associated endothelial cells that require this integrin for angiogenesis [1, 2] . Considering that angiogenesis contributes to tumor growth, and since LM609 is an IgG1 antibody with higher affinity for human versus mouse macrophage Fcγ receptors [48] , there may be additional benefits for this therapeutic strategy when applied to drug resistant tumors in humans, particularly when such agents are not combined with immunosuppressive drugs as they have been in the past [13] . In a broader sense, our work also highlights macrophage mediated ADCC as a potentially powerful approach for cancer targeted antibodies and suggests that antibody design may benefit from modifications to enable the exploitation of TAMs. (A) Co-enrichment of ITGB3 (β3 mRNA) with gene markers for additional tumor-infiltrating leukocyte cell types for TCGA datasets. The correlation between ITGB3 expression and combined markers of immune cell types was analyzed for the datasets listed in Figure 1 . The markers used for each cell type are indicated in Supplementary Table 2 . The table shows the average Pearson's correlation coefficients using the same immune cell type markers listed in Figure 1A. (B) Expression of ITGB3 mRNA for the TCGA pan-cancer dataset, graphed using cBioPortal.
Figure legends
Figure S2:
Tumor microarray slides were stained for β3 integrin and macrophage markers, CD68 and CD163. 
